Tag: anti-parkinson drugs market trends.

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Anti-Parkinson Drugs Market Valuation Change Between Now And 2029?

The market size of anti-parkinson drugs has seen a robust expansion in the previous years. It is projected to increase from $10.39 billion in 2024 to $10.96 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.5%. The escalated growth during the historical period can be credited to factors such as the aging population, the rise in disease incidence, the development of healthcare infrastructure, and progressive research advancements.

The market for anti-Parkinson medications is projected to see robust expansion in the coming years, with an expectation to reach “$13.48 billion by 2029” and a Compound Annual Growth Rate (CAGR) of 5.3%. The expected growth in the forecast period can be linked to increasing awareness, advancements in biotechnology, and the emergence of new markets. Significant trends anticipated during the forecast period include R&D investment, personalized healthcare, the development of disease-modifying therapies, drug redevelopment, remote telemedicine, biosimilars, and research partnerships.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

What External And Internal Drivers Are Influencing The Anti-Parkinson Drugs Market?

The escalating number of elderly people, coupled with the rising instances of Parkinson’s disease, is anticipated to propel the need for anti-Parkinson drugs in the market. Parkinson’s disease is most commonly found in individuals above the age of 60. As per the World Health Organization’s data from October 2022, it is predicted that globally, by 2030, one in every six individuals will be 60 years or older. By 2050, the global population within this age bracket will have doubled to 2.1 billion. Consequently, the enlarging older population is contributing to the expansion of the anti-parkinson drugs market.

Which Sub-Segments Are Driving Growth Within The Anti-Parkinson Drugs Market?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

What Future-Focused Trends Are Anticipated In The Anti-Parkinson Drugs Market?

Firms that are prominent players in the anti-Parkinson drugs market concentrate on the creation of cutting-edge therapeutic treatments such as motor fluctuations and dyskinesia, in an effort to improve the management of symptoms and reduce adverse effects. Motor fluctuations and dyskinesia often add complexity to Parkinson’s disease treatment, thus impacting patient health. For instance, PRODUODOPA was launched in January 2024 by AbbVie Inc., an American pharmaceutical firm. This treatment, consisting of foslevodopa/foscarbidopa, is the first 24-hour subcutaneous infusion therapy specifically designed to target severe motor fluctuations and dyskinesia in advanced stages of Parkinson’s disease, when other therapies have been ineffective. It continuously administers levodopa, which could potentially extend ‘on’ periods and enhance the control of symptoms.

Which Players Are Shaping The Competitive Landscape Of The Anti-Parkinson Drugs Market?

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

How Do Regional Dynamics Influence The Anti-Parkinson Drugs Market Performance?

North America was the largest region in the anti-Parkinson drugs market in 2024. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Estimated Industry Valuation for the Regenerative Medicine For Cartilage Sector?#_x000D_

The market size of anti-Parkinson’s medication has seen significant growth in the past few years. It is anticipated to expand from $10.39 billion in 2024 to $10.96 billion in 2025, with a compound annual growth rate (CAGR) of 5.5%. The rise during the historical period is a result of an aging population, a surge in disease prevalence, improved healthcare infrastructure, and advances in medical research._x000D_

_x000D_

The market for anti-parkinson drugs is predicted to witness robust expansion in the forthcoming years, escalating to an impressive “$13.48 billion by 2029 at a compound annual growth rate (CAGR) of 5.3%“. The projected growth during this forecast period can be credited to the rising cognizance, advancements in biotechnology and the emergence of new markets. Key trends that stand out in the forecast period encompass increased r&d investments, personalized medicinal approach, modifying disease-driven therapies, drug repositioning, telemedicine coupled with remote surveillance, biosimilars, and collaborative research efforts._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Regenerative Medicine For Cartilage Market?#_x000D_

The market for regenerative medicine for cartilage is predicted to expand due to the rising occurrence of osteoarthritis worldwide. Osteoarthritis is a type of degenerative joint disease primarily affecting the articular cartilage. The Arthritis Foundation has stated that by 2050, degenerative joint diseases like osteoarthritis are anticipated to affect a minimum of 130 million people globally. Autologous chondrocyte implantation and scaffold implants are among the most commonly employed treatments for osteoarthritis. As such, the growing prevalence of osteoarthritis is likely to stimulate the demand in the market for regenerative medicine for cartilage._x000D_

_x000D_

_x000D_

The anti-parkinson drugs market covered in this report is segmented – _x000D_

_x000D_

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs _x000D_

2) By Route of Administration: Oral, Injection, Transdermal _x000D_

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies _x000D_

_x000D_

Subsegments:_x000D_

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa _x000D_

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine _x000D_

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide _x000D_

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone _x000D_

5) By Anticholinergics: Benztropine, Trihexyphenidyl _x000D_

6) By Other Drugs: Amantadine, Apomorphine_x000D_

_x000D_

#What Are The Leading Trends And Opportunities In The Regenerative Medicine For Cartilage Sector?#_x000D_

Leading enterprises in the anti-Parkinson medications market are centred on advancing therapeutic solutions like motor fluctuations and dyskinesia in an attempt to improve symptom management and lessen harmful consequences. Such complications often make the treatment of Parkinson’s disease more challenging, impacting patient’s quality of life. For instance, PRODUODOPA was launched by AbbVie Inc., a pharmaceutical enterprise based in the U.S., in January 2024. This first-of-its-kind subcutaneous 24-hour infusion medication for advanced Parkinson’s disease is designed to help with serious motor fluctuations and dyskinesia when other remedies prove insufficient. Through constant delivery of levodopa, it potentially elevates ‘on’ time and enhances symptom management._x000D_

_x000D_

#Which Companies Currently Dominate The Competitive Landscape In The Regenerative Medicine For Cartilage Industry?#_x000D_

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc._x000D_

_x000D_

_x000D_

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Driving Demand In The Regenerative Medicine For Cartilage Market?#_x000D_

North America was the largest region in the anti-Parkinson drugs market in 2024. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa_x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Projected Market Size and Growth Rates for the Anti-Parkinson Drugs Market From 2025 To 2029?

The market for anti-Parkinson’s medications has recently seen significant expansion. It is projected to increase from $10.39 billion in 2024 to $10.96 billion in 2025, at a 5.5% compound annual growth rate (CAGR). The reasons for the growth during the historical period can be attributed to factors such as the aging population, rising incidence of the disease, improved healthcare infrastructure and progressive advancements in research.

Predictions suggest a robust expansion in the anti-parkinson drugs market over the approaching years. By 2029, the market size is forecasted to reach $13.48 billion, growing at a compound annual growth rate (CAGR) of 5.3%. This significant surge in the forecast period can be ascribed to several contributing factors such as heightened public awareness, advancements in biotechnology, and newly emerging markets. On the horizon, the forecast period is likely to experience certain key trends including investments in research and development, a rise in personalized medicine, the advent of disease-modifying therapies, increased focus on drug repurposing, the broadening reach of telemedicine and remote monitoring, the growth of biosimilars, and amplified research partnerships.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

What Are the Core Market Drivers Propelling Growth in the Anti-Parkinson Drugs Industry?

The rise in the elderly population coupled with escalating instances of Parkinson’s disease (PD) are anticipated to fuel the demand within the anti-Parkinson drugs market. PD is typically witnessed in individuals above 60 years of age. For example, findings from the World Health Organization in October 2022, revealed that a global health agency from the United States predicted that by 2030, 1 in every 6 individuals globally will be aged 60 or older. Furthermore, by 2050, the number of people in this age bracket is expected to double to 2.1 billion. Consequently, the growth of the anti-Parkinson drugs market is spurred on by the expanding geriatric population.

How Is the Anti-Parkinson Drugs Market Segmented?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp

Which Regions Are Driving the Next Phase of the Anti-Parkinson Drugs Market Growth?

North America was the largest region in the anti-Parkinson drugs market in 2024. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What Key Market Trends and Innovations Are Shaping the Future of the Anti-Parkinson Drugs Industry?

Leading companies in the anti-Parkinson drugs market are directing their efforts towards creating advanced therapeutic solutions such as motor fluctuations and dyskinesia, aiming to improve symptom management and reduce side effects. Such conditions often add to the complexities of Parkinson’s disease treatments, impacting the patient’s quality of life. For instance, in January 2024, US pharmaceutical company AbbVie Inc. introduced PRODUODOPA. This product, also known as foslevodopa/foscarbidopa, is a first-of-its-kind subcutaneous 24-hour infusion therapy for addressing severe motor fluctuations and dyskinesia in cases of advanced Parkinson’s disease when other treatments prove ineffective. PRODUODOPA provides a continuous supply of levodopa, which could potentially enhance ‘on’ time and better symptom control.

View the full report here:

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

How Is the Anti-Parkinson Drugs Market Defined and What Are Its Core Parameters?

Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson’s disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic’s negative effects.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Anti-Parkinson Drugs Market Expected to Grow Between 2025 And 2029?

The market size for anti-Parkinson’s drugs has seen robust growth in the past few years. The market is projected to expand from $10.37 billion in 2024 to $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The escalating trend during the historical period can be credited to factors such as the aging population, a rise in disease incidence, improvements in healthcare infrastructure, and advancements in medical research.

What Growth Rate Is Anticipated for the Anti-Parkinson Drugs Market in the Coming Years?

The market for anti-Parkinson’s medication is anticipated to witness considerable expansion in the upcoming years, forecasted to reach a value of $13.73 billion by 2029, growing at an annual compounded rate of 5.5%. This predicted growth in the forecast period is largely owing to increasing awareness, advancements in biotechnology, and the emergence of new markets. The forecast period is also expected to see trends such as investments in research and development, personalized medical treatments, therapies that modify diseases, drug repurposing, application of telemedicine and remote supervision, use of biosimilars, and research collaborations.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Who Are the Leading Companies in the Anti-Parkinson Drugs Market?

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

What Are the Key Drivers of the Anti-Parkinson Drugs Market?

The rising elderly population, along with escalating instances of Parkinson’s disease (PD), typically seen in individuals above 60, is expected to fuel the demand in the anti-Parkinson drugs market. The World Health Organization, a US health agency, reported in October 2022 that by 2030, 1 in every 6 people worldwide will be 60 or older. This number is anticipated to double by 2050, reaching 2.1 billion. These factors point towards a growing geriatric population, thereby boosting the growth of the anti-Parkinson drugs market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp

What Are the Key Market Segments in the Anti-Parkinson Drugs Industry?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

What Are the Latest Trends in the Anti-Parkinson Drugs Market?

Major firms in the anti-Parkinson medication market are concentrating on the development of superior treatment solutions such as motor fluctuations and dyskinesia, aimed at improving symptom control and reducing side effects. These motor fluctuations and dyskinesia often add complexity to Parkinson’s disease treatment and impact patient wellness. Illustratively, in January 2024, AbbVie Inc., a pharmaceutical company based in the US, introduced PRODUODOPA. PRODUODOPA (foslevodopa/foscarbidopa) is a unique subcutaneous 24-hour infusion therapy for advanced Parkinson’s disease, specifically targeting severe motor fluctuations and dyskinesia when alternative therapies are ineffective. It provides a continuous supply of levodopa, potentially extending the ‘on’ period and enhancing symptom control.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

What Are the Key Regional Markets in the Anti-Parkinson Drugs Industry?

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462

This Report Delivers Insight On:

1. How big is the anti-parkinson drugs market, and how is it changing globally?

2. Who are the major companies in the anti-parkinson drugs market, and how are they performing?

3. What are the key opportunities and risks in the anti-parkinson drugs market right now?

4. Which products or customer segments are growing the most in the anti-parkinson drugs market?

5. What factors are helping or slowing down the growth of the anti-parkinson drugs market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Anti-Parkinson Drugs Market?

The increasing geriatric population and the rise in Parkinson’s disease (PD) cases are significant factors contributing to the growth of the anti-Parkinson drugs market. PD is most commonly diagnosed in individuals over the age of 60, and with the global aging population, the demand for treatments is expected to escalate. For instance, the World Health Organization projects that by 2030, 1 in 6 people will be 60 years or older, and by 2050, this number will double to 2.1 billion. This surge in the elderly population will likely drive the demand for anti-Parkinson drugs.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

#What Growth Opportunities Will Drive the Anti-Parkinson Drugs Market’s CAGR Through 2034?

The anti-parkinson drugs market has grown steadily and strongly. It is projected to expand from $10.37 billion in 2024 to $11.08 billion in 2025, reflecting a CAGR of 6.9%. Key factors behind this growth include an aging population, rising incidence of Parkinson’s disease, healthcare infrastructure development, and research advancements.

The anti-Parkinson’s drugs market is expected to experience strong growth, reaching $13.73 billion by 2029 at a CAGR of 5.5%. Growth will be driven by increased awareness, biotechnological advancements, and emerging markets. Key trends include R&D investment, personalized medicine, disease-modifying therapies, drug repurposing, telemedicine, remote monitoring, biosimilars, and research collaborations.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462

What Are the Most Significant Market Trends Transforming theAnti-Parkinson Drugs Market?

In the anti-Parkinson drugs market, companies are introducing advanced therapeutic options to better manage motor fluctuations and dyskinesia in patients. For instance, in January 2024, AbbVie Inc. launched PRODUODOPA (foslevodopa/foscarbidopa), a 24-hour subcutaneous infusion therapy designed to improve symptoms in patients with advanced Parkinson’s disease who experience severe motor complications.

What Are the Top Market Players Propelling the Growth of theAnti-Parkinson Drugs Industry?

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Which Primary Segments of the Anti-Parkinson Drugs Market Are Driving Growth and Industry Transformations?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Anti-Parkinson Drugs Market?# Market?

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Reports Similar to the Global Anti-Parkinson Drugs Market 2025, By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Electrophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/electrophysiology-devices-and-equipment-global-market-report

Brain Monitoring Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/brain-monitoring-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What fueled the previous growth in the anti-parkinson drugs market?

The market size for anti-parkinson drugs has experienced considerable growth recently. The forecast suggests an upsurge from $10.37 billion in 2024 to approximately $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. Factors responsible for this progression during the historical period include an aging population, surging disease prevalence, improvements in healthcare infrastructure, and advancements in medical research.

What will be the anti-parkinson drugs market size in the future?

The market for anti-Parkinson’s medications is forecasted to experience substantial expansion in the forthcoming years. It is estimated to increase to a value of $13.73 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this projected growth during the forecast period include enhanced awareness, advancements in biotechnology, and emerging markets. The future trends within the same frame include investments in research and development, the advent of personalized medicine, therapies that modify the disease course, drug repurposing, the rise of telemedicine and remote patient monitoring, the impact of biosimilars, and the role of research collaborations.

Get your anti-parkinson drugs market report here!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

What main drivers are fueling expansion in the anti-parkinson drugs market?

The escalating number of older adults and the rising instances of Parkinson’s disease is anticipated to fuel the demand for the anti-Parkinson’s drugs market. Parkinson’s disease is predominantly observed in individuals over 60 years old. For example, in October 2022, the World Health Organization, an American health institution, reported that 1 in every 6 people globally will be aged 60 or above by the year 2030, and this figure is expected to double (reaching 2.1 billion) by 2050. Consequently, the expansion of the elderly population is catalyzing the anti-Parkinson’s drugs market growth.

What key areas define the segmentation of the global anti-parkinson drugs market?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Who are the dominant players expanding their reach in the anti-parkinson drugs market?

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

How are evolving market trends shaping anti-parkinson drugs Strategies?

Major firms in the anti-Parkinson drugs market are concentrating their efforts on creating cutting-edge therapeutic solutions like motor fluctuations and dyskinesia with a focus on enhancing symptom management and reducing adverse effects. Motor fluctuations and dyskinesia typically make Parkinson’s disease treatment more complex and have an impact on patient welfare. For example, in January 2024, AbbVie Inc., an American pharmaceutical firm, introduced PRODUODOPA. PRODUODOPA(foslevodopa/foscarbidopa), the first-ever subcutaneous 24-hours infusion therapy specially designed for advanced Parkinson’s disease, focuses on extreme motor fluctuations and dyskinesia when other treatments cannot provide sufficient help. This solution continuously provides levodopa, potentially maximizing ‘on’ time and improving symptom management.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462

Which regions are emerging as leaders in the anti-parkinson drugs market?

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Electrophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/electrophysiology-devices-and-equipment-global-market-report

Brain Monitoring Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/brain-monitoring-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Factors Are Driving the Anticipated Growth Rate of the Anti-Parkinson Drugs Market Through 2034?

The market size for anti-parkinson drugs has experienced considerable growth recently. The forecast suggests an upsurge from $10.37 billion in 2024 to approximately $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. Factors responsible for this progression during the historical period include an aging population, surging disease prevalence, improvements in healthcare infrastructure, and advancements in medical research.

The market for anti-Parkinson’s medications is forecasted to experience substantial expansion in the forthcoming years. It is estimated to increase to a value of $13.73 billion by 2029, with a compound annual growth rate (CAGR) of 5.5%. Factors contributing to this projected growth during the forecast period include enhanced awareness, advancements in biotechnology, and emerging markets. The future trends within the same frame include investments in research and development, the advent of personalized medicine, therapies that modify the disease course, drug repurposing, the rise of telemedicine and remote patient monitoring, the impact of biosimilars, and the role of research collaborations.

Which Factors Are Enhancing the Growth of the Anti-Parkinson Drugs Market?

The escalating number of older adults and the rising instances of Parkinson’s disease is anticipated to fuel the demand for the anti-Parkinson’s drugs market. Parkinson’s disease is predominantly observed in individuals over 60 years old. For example, in October 2022, the World Health Organization, an American health institution, reported that 1 in every 6 people globally will be aged 60 or above by the year 2030, and this figure is expected to double (reaching 2.1 billion) by 2050. Consequently, the expansion of the elderly population is catalyzing the anti-Parkinson’s drugs market growth.

Explore Comprehensive Insights Into The Global Anti-Parkinson Drugs Market With A Free Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

Who Are the Major Industry Leaders Accelerating Growth in the Anti-Parkinson Drugs Market?

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

Which Current Trends Are Having the Most Impact on the Anti-Parkinson Drugs Market?

Major firms in the anti-Parkinson drugs market are concentrating their efforts on creating cutting-edge therapeutic solutions like motor fluctuations and dyskinesia with a focus on enhancing symptom management and reducing adverse effects. Motor fluctuations and dyskinesia typically make Parkinson’s disease treatment more complex and have an impact on patient welfare. For example, in January 2024, AbbVie Inc., an American pharmaceutical firm, introduced PRODUODOPA. PRODUODOPA(foslevodopa/foscarbidopa), the first-ever subcutaneous 24-hours infusion therapy specially designed for advanced Parkinson’s disease, focuses on extreme motor fluctuations and dyskinesia when other treatments cannot provide sufficient help. This solution continuously provides levodopa, potentially maximizing ‘on’ time and improving symptom management.

Secure Your Global Anti-Parkinson Drugs Market Report Now for Fast and Efficient Delivery!

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

How Are the Key Segments of the Anti-Parkinson Drugs Market Driving Opportunities and Innovations?

The anti-parkinson drugs market covered in this report is segmented –

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:

1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa

2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine

3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide

4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone

5) By Anticholinergics: Benztropine, Trihexyphenidyl

6) By Other Drugs: Amantadine, Apomorphine

Which Regions Are Key Players in the Growth of the Anti-Parkinson Drugs Market?

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

How Is the Definition of the Anti-Parkinson Drugs Market Impacting Future Growth?

Anti-Parkinson drug is a term used to describe the medications that are mostly used to treat Parkinson’s disease. They are not psychiatric medications, so they cannot legally be used to treat mental health issues. However, a doctor or psychiatrist may recommend one of these medications in addition to an antipsychotic to lessen some of the antipsychotic’s negative effects.

Browse Through More Similar Reports By The Business Research Company:

Dermatology Drugs Global Market Report 2022

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Electrophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/electrophysiology-devices-and-equipment-global-market-report

Brain Monitoring Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/brain-monitoring-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: